Filtered By:
Cancer: Brain Cancers
Therapy: Cancer Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research

Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo.
Abstract Activation of signal transducer and activator of transcription3 (STAT3) is a hallmark of several types of cancer. Failure to inhibit STAT3 expression by injection of siRNA for STAT3 directly to Balb/c mice led us to adopt alternative means. We formulated nanoparticle-based encapsulation of siRNA (NsiRNA) with polyethylenimine (PEI) and poly (lactide-co-glycolide) (PLGA) and characterized them. The siRNA treated and NsiRNA-treated cells were subjected separately to different assay systems. We also checked if NsiRNA could cross the Blood Brain Barrier (BBB). Cell viability reduced dramatically in A549 cells...
Source: Toxicology Letters - January 16, 2014 Category: Toxicology Authors: Das J, Das S, Paul A, Samadder A, Bhattacharyya SS, Khuda-Bukhsh AR Tags: Toxicol Lett Source Type: research

CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in  vivo.
CD-PLLD co-delivering docetaxel and MMP-9 siRNA plasmid for nasopharyngeal carcinoma therapy in vivo. Mol Med Rep. 2017 Jun 07;: Authors: Liu T, Wu X, Wang Y, Hou X, Jiang G, Wu T, Xie H, Xie M Abstract The co-delivery of a drug and a target gene has become a primary strategy in cancer therapy. Based on our previous study, a synthesized star‑shaped co‑polymer consisting of β‑cyclodextrin (CD) and a poly(L‑lysine) dendron (PLLD) was used to co-deliver docetaxel (DOC) and matrix metalloproteinase 9 (MMP‑9) small interfering RNA, via CD‑PLLD/DOC/MMP‑9 complexes, into mice implanted with HN...
Source: Molecular Medicine Reports - October 29, 2017 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Detailed Dissection of UBE3A-Mediated DDI1 Ubiquitination
Discussion Poly-ubiquitinated proteins targeted for degradation might be recognized directly by proteasomal receptors or by proteasomal shuttling proteins. The first shuttling proteins – Ddi1, Rad23 and Dsk2 – were identified and characterized in Saccharomyces cerevisiae (Lambertson et al., 1999; Kaplun et al., 2005). Proteasomal shuttles contain an N-terminal ubiquitin-like (UBL) domain that interacts with the 26S proteasome (Finley, 2009), and a C-terminal ubiquitin-binding domain domain (UBD) that binds to ubiquitin or poly-ubiquitin chains (Bertolaet et al., 2001). When ubiquitinated, substrates are capt...
Source: Frontiers in Physiology - May 2, 2019 Category: Physiology Source Type: research

Down-regulation of anti-apoptotic genes in tumor cell lines is facilitated by suppression of OCT4B1
Conclusions It may possibly be concluded that suppression of OCT4B1 can lead to apoptosis in tumor cell lines and this is at least facilitated via down-regulation of examined anti-apoptotic genes. Accordingly, suppression of OCT4B1 may probably be considered as useful tool in cancer therapy and research.
Source: Advances in Medical Sciences - May 10, 2016 Category: Biomedical Science Source Type: research

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer
CONCLUSION: TrkB/BDNF signaling may be a new therapeutic target for PDAC. Therapies targeting TrkB/BDNF signaling may be a conclusive cancer therapy for refractory solid cancer.PMID:34281873 | DOI:10.21873/anticanres.15205
Source: Cell Research - July 20, 2021 Category: Cytology Authors: Yasuhiro Oyama Shinjiro Nagao Lin Na Kosuke Yanai Masayo Umebayashi Katsuya Nakamura Shuntaro Nagai Akiko Fujimura Akio Yamasaki Kazunori Nakayama Takashi Morisaki Hideya Onishi Source Type: research

Biodegradable and Bioreducible Poly(beta ‐amino ester) Nanoparticles for Intracellular Delivery to Treat Brain Cancer
This article is protected by copyright. All rights reserved.
Source: AIChE Journal - February 28, 2017 Category: Science Authors: Yuan Rui, Gabriella Qui ñones, Jordan J. Green Tags: perspective Source Type: research

Cancers, Vol. 11, Pages 406: Alpha6-Integrin Regulates FGFR1 Expression through the ZEB1/YAP1 Transcription Complex in Glioblastoma Stem Cells Resulting in Enhanced Proliferation and Stemness
Catherine SEVA Glioblastoma (GBM) is the most lethal primary brain tumor in adults and is known to be particularly aggressive and resistant to anti-cancer therapies, mainly due to the presence of GBM stem cells (GBMSC). By in vitro approaches supported by analysis from patients’ databases, we determined how α6-integrin and Fibroblast Growth Factor Receptor 1 (FGFR1) work in concert to regulate proliferation and stemness of GBMSC. We showed that α6-integrin regulates the expression of FGFR1 and its target gene Fokhead Box M1 (FOXM1) via the ZEB1/YAP1 transcription complex. Thes...
Source: Cancers - March 21, 2019 Category: Cancer & Oncology Authors: Aline KOWALSKI-CHAUVEL Valerie GOUAZE-ANDERSSON Laurent BARICAULT Elodie MARTIN Caroline DELMAS Christine TOULAS Elizabeth COHEN-JONATHAN-MOYAL Catherine SEVA Tags: Article Source Type: research

Abstract 3954: SAT1 (Spermidine/spermine-N1-acetyltrasferase 1) promotes radiation resistance in glioblastoma multiforme
The objective of this study is to explore the role of SAT1 in radioresistance with the purpose of targeting SAT1 as a means to sensitize tumors. The knockdown of SAT1 using, shRNA and siRNA approaches, in multiple cell lines and neurosphere lines results in sensitization of GBM cells to radiation in colony formation assays. This was seen specifically in G2/M and S phases, leading to the hypothesis that SAT1 plays a role in homologous recombination (HR). By measuring HR in the DR-GFP reporter system, we confirmed that SAT1 promotes HR, since depletion of SAT1 results in decrease in HR. To test whether SAT1 depletion sensiti...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Brett-Morris, A., Welford, S. M., Bar, E., Spina, R., Wright, B., Zhang, J., Lu, J., Seo, Y. Tags: Tumor Biology Source Type: research

Abstract 4459: Characterization of a novel magnetic nanoparticles formulation for cancer therapeutic applications
We have successfully engineered a magnetic nanoparticles (MAG-NPs) formulation using a multi-layer approach which can be used for drug/gene/biomolecule delivery, hyperthermia, and magnetic resonance imaging (MRI) applications in cancer therapeutics. Overcoming nanoparticles clearance by the immune system remains a major challenge. This formulation is designed to provide an additional surface layer as molecular “authentication” that the body does not recognize as foreign material. The interaction between the surface of nanoparticles and plasma proteins leads to nanoparticle-protein complex which determines the rational ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yallapu, M. M., Chauhan, N., Othman, S. F., Khalilzad-Sharghi, V., Jaggi, M., Chauhan, S. C. Tags: Cancer Chemistry Source Type: research

SAT1 Regulates BRCA1 Expression and HR in GBM
Glioblastoma multiforme (GBM) is the most common and severe form of brain cancer. The median survival time of patients is approximately 12 months due to poor responses to surgery and chemoradiation. To understand the mechanisms involved in radioresistance, we conducted a genetic screen using an shRNA library to identify genes in which inhibition would sensitize cells to radiation. The results were cross-referenced with the Oncomine and Rembrandt databases to focus on genes that are highly expressed in GBM tumors and associated with poor patient outcomes. Spermidine/spermine-N1-acetyltransferase 1 (SAT1), an enzyme involved...
Source: Cancer Research - November 30, 2014 Category: Cancer & Oncology Authors: Brett-Morris, A., Wright, B. M., Seo, Y., Pasupuleti, V., Zhang, J., Lu, J., Spina, R., Bar, E. E., Gujrati, M., Schur, R., Lu, Z.-R., Welford, S. M. Tags: Molecular and Cellular Pathobiology Source Type: research

TGF-β/Smad2/3 signal pathway involves in U251 cell proliferation and apoptosis.
In this study, we identify that the TGF-β/Smad2/3 signal pathway is activated in human brain gliomas cells; inhibitor (SB203580) and siRNA against Smad2/3 quickly inhibited the phosphorylation of Smad2 and 3, expression of its major downstream gene, Ki-67, arrested cells in the G2/M phase and induced apoptosis of cells. The findings suggest that TGF-β/Smad2/3 pathway play a key role in U251 cell growth and metastasis, which suggests its potential role in the molecular therapy of brain cancer. PMID: 25701598 [PubMed - as supplied by publisher]
Source: Gene - February 18, 2015 Category: Genetics & Stem Cells Authors: Zhao HW, Li YW, Feng R, Yu JB, Li J, Zhang Y, Li JC, Wang YX Tags: Gene Source Type: research

Functional Assays for Specific Targeting and Delivery of RNA Nanoparticles to Brain Tumor
Cumulative progress in nanoparticle development has opened a new era of targeted delivery of therapeutics to cancer cells and tissue. However, developing proper detection methods has lagged behind resulting in the lack of precise evaluation and monitoring of the systemically administered nanoparticles. RNA nanoparticles derived from the bacteriophage phi29 DNA packaging motor pRNA have emerged as a new generation of drugs for cancer therapy. Multifunctional RNA nanoparticles can be fabricated by bottom-up self-assembly of engineered RNA fragments harboring targeting (RNA aptamer or chemical ligand), therapeutic (siRNA, miR...
Source: Springer protocols feed by Biotechnology - April 25, 2015 Category: Biotechnology Source Type: news